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Abstract
Background: Topical therapy is effective for dry eye, and its prolonged effects should help in maintaining the quality of
life of patients with dry eye. We previously reported that the oral administration of rebamipide (Reb), a mucosal
protective agent, had a potent therapeutic effect on autoimmune lesions in a murine model of Sjo¨gren’s syndrome (SS).
However, the effects of topical treatment with Reb eyedrops on the ocular lesions in the murine model of SS are
unknown.
Methods and Finding: Reb eyedrops were administered to the murine model of SS aged 4–8 weeks four times daily.
Inflammatory lesions of the extraorbital and intraorbital lacrimal glands and Harderian gland tissues were histologically
evaluated. The direct effects of Reb on the lacrimal glands were analyzed using cultured lacrimal gland cells. Tear secretions
of Reb-treated mice were significantly increased compared with those of untreated mice. In addition to the therapeutic
effect of Reb treatment on keratoconjunctivitis, severe inflammatory lesions of intraorbital lacrimal gland tissues in this
model of SS were resolved. The mRNA expression levels of IL-10 and mucin 5Ac in conjunctival tissues from Reb-treated
mice was significantly increased compared with those of control mice. Moreover, lactoferrin production from lacrimal gland
cells was restored by Reb treatment.
Conclusion: Topical Reb administration had an anti-inflammatory effect on the ocular autoimmune lesions in the murine
model of SS and a protective effect on the ocular surfaces.
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Introduction
Sjo¨gren’s syndrome (SS) is an autoimmune disease character-
ized by lymphocyte infiltration and destruction of the salivary and
lacrimal glands [1]. Dry eye and dry mouth are the main clinical
manifestations of SS. In particular, many patients with SS suffer
from keratoconjunctivitis due to severe dry eye. The typical
symptoms of keratoconjunctivitis sicca include burning, itchiness,
pain in the eyes, or tired eyes [2,3]. The quality of life of patients
with SS is significantly impaired; therefore, an effective therapy
for ocular lesions would improve the quality of life of these
patients.
In a previous report, we demonstrated the therapeutic effects of
orally administered rebamipide (Reb), a mucosal protective agent,
on autoimmune lesions in thymectomized NFS/sld mice, a murine
model for SS [4]. Reb had two potent effects including the
immunosuppressive activity and the antiapoptotic activity in target
cells [4]. In addition, recent studies have shown that Reb increased
the barrier function of the intestinal mucosa, gastric mucosa, and
corneal epithelial cells [5–8]. However, the possible effects of Reb
on ocular lesions in an animal model of SS have not been
determined.
Various tissues in the orbit comprise the eyeball, fat tissue,
muscles, connective tissue, and lacrimal glands [9]. Although
evidence indicates that ocular lesions in SS involve injury to the
epithelial cells of the conjunctiva and cornea, the sources of
inflammation of the lacrimal glands or accessory glands in the
orbit remain unclear.
In the present study, treatment with Reb eyedrops was
administered to our model of primary SS [10] to determine the
therapeutic effects of Reb on ocular inflammatory lesions in SS.
Our findings could be important for indicating an effective topical
medication for patients with SS.
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Results
The effects of Reb eyedrops on tear secretion in the
murine model of SS
NFS/sld mice were thymectomized 3 days (3d-Tx) after birth,
and 3d-Tx female mice aged 4 weeks were used for experiments.
Reb eyedrops (0%, 0.3%, and 1%) were administered four times
daily to mice aged 4–8 weeks. Tear volumes were measured to
determine the effects of Reb treatment on tear fluid secretion. The
average decreased tear volumes in 0% Reb-treated mice were
restored by treatment with 0.3% and 1% Reb eyedrops and were
similar to tear volumes of untreated non-Tx mice (Figure 1).
The effects of Reb eyedrops on ocular lesions in the
murine model of SS
Mice were assessed for corneal epithelial disorders using
fluorescein staining. The corneal epithelium of 3d-Tx mice
showed sparse or dense superficial punctate keratitis similar to
that of patients with SS, whereas the corneal epithelium of non-Tx
mice were not detectably stained (Figure 2A). The corneal
epithelium of Reb-treated (0.3% and 1%) mice was improved
(Figure 2A). The fluorescein staining scores of Reb-treated 3d-Tx
mice were significantly lower compared with of control mice in a
dose-dependent manner (Figure 2B).
Histopathological changes in inflammatory lesions of
lacrimal gland tissues after treatment with Reb eyedrops
The lacrimal glands include the extraorbital and intraorbital
glands. We previously reported that inflammatory lesions of the
salivary glands, but not those of the extraorbital lacrimal glands
(Ex-Lg), resolved after the oral administration of Reb [4]. In
addition to the Ex-Lg, the intraorbital lacrimal glands (In-Lg) and
Harderian glands (Hg) are known to maintain ocular mucosal
tissues [9]. In-Lg and Hg tissues of untreated non-Tx mice are
shown in Figure 3A. In this model of SS, inflammatory lesions
were detected in the Ex-Lg, In-Lg, and Hg (Figure 3B).
Mononuclear lymphocytes are infiltrated around the duct or
adjacent the gland cells in lacrimal gland tissues of 3d-Tx mice
(Figure 3B). No changes were observed in inflammatory lesions
of the Ex-Lg and Hg of Reb-treated mice (Figure 3B). In
contrast, inflammatory lesions in the In-Lg of Reb-treated mice
improved (Figure 3B). Moreover, the histological scores for the
In-Lg, but not Ex-Lg, of 0.3% and 1% Reb-treated mice were
significantly lower compared with those of 0% Reb-treated control
mice (Figure 3C, D). The scores for Hg were not changed by
Reb eyedrop treatment (Figure 3E).
The anti-inflammatory effects of Reb on the ocular
lesions in the murine model of SS
To determine the molecular mechanisms underlying the
therapeutic effects of Reb eyedrop treatment, the mRNA
expression levels of immunoregulatory cytokines and protective
proteins [11–13], including IL-10, TGF-b, and mucin 5AC, in
conjunctival tissues were analyzed using real-time RT-PCR
(Figure 4A, B, and C). The mRNA expression levels of IL-10
and mucin 5AC in Reb-treated mice were significantly increased
compared with those in Reb 0%-treated mice (Figure 4B, C).
The effect of Reb on lactoferrin secretion by lacrimal
glands in the murine model of SS
The results of ELISA showed that the concentration of the anti-
inflammatory factor lactoferrin [14–17] in the tears of Reb-treated
mice was significantly increased compared with that of 0% Reb-
treated mice (Figure 5A). In the analysis of the mRNA
expressions levels of lactoferrin in cultured tissues using real-time
RT-PCR, the mRNA expression levels of lactoferrin in cultured
lacrimal gland tissues were more promoted by addition of Reb
(Figure 5B).
Increased expression of lactoferrin in In-Lg by Reb
eyedrop therapy
Using immunohistochemistry, we found that the expression of
lactoferrin in In-Lg tissues of the murine model of SS was
significantly reduced compared with that in of normal In-Lg
tissues (Figure 6). Further, immune cells such as macrophages
were positive for lactoferrin (Figure 6). Treatment with Reb
restored lactoferrin expression in In-Lg tissues of the murine
model of SS (Figure 6).
Discussion
Reb has been widely applied as a gastroprotective drug against
gastritis and gastric ulcers, and it exhibits mucin secretagogue
activity, anti-inflammatory actions, and antibacterial effects
[6,7,18,19]. In a previous report, we demonstrated that the oral
administration of Reb had a therapeutic effect on autoimmune
lesions of the salivary glands in thymectomized NFS/sld mice, a
murine model of SS [4]. In that paper, Reb treatment inhibited
the activation of effector T cells, and the production of Th1-type
cytokines such as IL-2 and IFN-c and was associated with
decreased NF-kB activity [4]. Moreover, the serum autoantibody
levels were clearly decreased after the oral administration of Reb
[4]. Although oral administration of Reb at a low concentration
resolved the inflammatory lesions of the salivary glands in our
murine model of SS and restored saliva secretion, inflammatory
lesions of the lacrimal glands were not resolved by the oral
administration of Reb at the same dose [4]. Moreover, tear
secretion in this model of SS was not recovered after oral
administration [4]. On the other hand, Kinoshita et al.
demonstrate that 2% rebamipide ophthalmic suspension is
effective in improving both the objective signs and subjective
symptoms of dry eye patients including primary or secondary SS
Figure 1. Therapeutic effects of Reb eyedrop administration on
tear secretion in the murine model of SS. Average tear volumes
after pilocarpine administration (2.5 mg/kg) were measured for 5 min
(0–5 min and 5–10 min). Results are expressed as means 6 SD for 5
mice per group. Control, nonthymectomized (non-Tx) NFS/sld mice.
** P,0.005.
doi:10.1371/journal.pone.0098390.g001
Effective Therapy of SS Lesion by Reb Eyedrop
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patients (16.9%) [20]. Our findings as for the objective signs
including fluorescein corneal staining score and pathological score
of intraorbital lacrimal gland in rebamipide-treated SS model mice
are similar to those in dry eye patients. We believe that our results
show the anti-inflammatory effects of rebamipide on the ocular
lesions in murine suggest the same effects on human ocular
surface, and the effect contribute improving subjective symptoms.
Our results would be useful for establishing more effective
therapeutic strategy of SS with rebamipide.
In our murine model of SS, neonatal thymectomy was
performed to induce the breakdown of central or peripheral
tolerance to trigger autoimmunity [10,21]. The thymic function of
almost all patients with SS may be intact. Although MRL/lpr or
NZB/NZW F1 mice are also well known to be an animal model of
SS, they are considered as a model of secondary SS with systemic
autoimmune lesions [22–24]. In contrast, thymectomized NFS/sld
mice have been established as a model of primary SS [10]. As
inflammatory lesions in this model are localized in salivary and
lacrimal glands, resembling human primary SS, and immune
phenotypes and responses including cytokine profile, autoantibody
production, or antigen-specific T cell responses are similar to those
of human SS, this animal model has been used for analyzing the
pathogenesis of SS and establishing new therapeutic strategies
[25–27]. In addition, autoimmune lesions have an earlier onset in
young mice (aged 6–8 weeks), with the frequency of onset being
almost 100%. Therefore, this model is considerably useful for the
study of SS despite several large differences between humans and
mice. On the other hand, there are no differences in body weight,
gross pelage aspect, reproductive capacity between control and
thymectomized NFS/sld mice. As for immunological aspects such
as decreased T cell number, enhanced Th1-type cytokine
production, and autoantibody production in addition to autoim-
mune lesions in salivary and lacrimal glands were observed in the
thymectomized mice [25–27].
With respect to the endocrine system, female-specific autoim-
mune lesions were observed in thymectomized NFS/sld mice,
resembling human SS [10,21]. Moreover, autoimmune lesions in
the murine model of SS that underwent ovariectomy were
markedly enhanced compared with those in sham-operated mice,
suggesting that sex hormones such as estrogen play a key role in
the onset of autoimmune lesions in SS [28]. Although the
relationship between thymectomy and endocrine system in this
model is still unclear, some interaction may occur between the
immune and endocrine systems to trigger the onset of SS.
In the present study, we show that Reb eyedrops had
therapeutic effects on ocular lesions and tear secretion in
thymectomized NFS/sld mice. Thus, inflammatory lesions of the
In-Lg, but not Ex-Lg, in the murine model had clearly improved
after Reb eyedrop treatment. This finding suggests that Reb exerts
a potent anti-inflammatory action against an autoimmune
response in the exocrine glands, and it is also exerts protective
effects on the ocular surface. Because of the anatomical structure
of the orbit, drugs are unable to reach the Ex-Lg. Considering the
therapeutic effect of Reb eyedrops on the In-Lg, it is possible that
In-Lg plays an important role in maintaining ocular and orbital
tissues.
Ex-Lg tissues were analyzed in studies of most animal models of
SS [29]. Because the systemic exocrine glands are targeted in SS,
In-Lg tissues are also targets. Similarly, the minor salivary glands
in the lip, oral palate, or oral mucosa are known to be targeted in
SS as well as the submandibular, sublingual, and parotid glands,
which are the major salivary glands [30]. The Hg and In-Lg are
present in mice, but not in humans, and act as accessories to the
lacrimal glands by secreting mucus or lipids [31], while the
Figure 2. Effect of Reb eyedrops on the ocular lesions in the murine model of SS. (A) Ocular surface lesions in Reb-treated mice were
examined using fluorescein staining of the ocular surface. Representative photomicrographs for each group are shown. (B) The scores for corneal
epithelial disorders. Results are expressed as mean 6 SD for five mice per group. *P,0.05, **P,0.005.
doi:10.1371/journal.pone.0098390.g002
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accessory lacrimal glands are present in the conjunctival tissue of
humans. Because Reb eyedrops exerted no effects on these
inflammatory lesions in the Ex-Lg and Hg, anatomical or
functional differences between the lacrimal glands may influence
their efficiency. Much of the tear volume seems to be secreted by
the Ex-Lg and Hg. However, the In-Lg may supply tears for dry
eye due to the dysfunction of the major lacrimal glands to
maintain the ocular surface. It is possible that the In-Lg may play a
key role in the speedy recovery from dryness of the ocular surface.
Hg in mice is known to play an important role in maintenance of
ocular functions, and it was reported that pilocarpine can stimulate
significant tear secretion from Harderian gland in mice [32,33].
Although inflammatory lesions of Hg in Reb-treated SS model was
not recovered, any protective effect of Reb may influence the
gland to promote tear secretion. We believe that rebamipide may
act as both an anti-inflammatory and mucosa-protective agent.
The mRNA expression levels of several key factors that mediate
conjunctiva tissue function, including IL-10 and mucin 5AC, were
changed by Reb treatment. Further, our findings suggest that the
effect of Reb through the upregulation of lactoferrin in the
lacrimal glands may play a key immunoregulatory role in
autoimmune responses. It was reported that lactoferrin targets T
Figure 3. Inflammatory lesions of lacrimal glands and Harderian glands (Hg) in Reb-treated murine model of SS. (A) Anatomical
positions of the intraorbital lacrimal glands (In-Lg) and Hg of normal mice. C, cornea; Eb, eyeball. Scale bar = 200 mm (left), 100 mm (right). (B)
Inflammatory lesions in the extraorbital lacrimal glands (Ex-Lg), In-Lg, and Hg of Reb-treated murine model of SS. Photomicrographs are
representative of five mice per group. Scale bars = 200 mm. (C, D, E) Histological scores of inflammatory lesions in the Ex-Lg (C), In-Lg (D), and Hg (E).
Results expressed as mean 6 SD for five mice per group. *P,0.05.
doi:10.1371/journal.pone.0098390.g003
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cells to maintain mucosal immunity [34]. Moreover, it was
demonstrated that lactoferrin prevents lacrimal gland dysfunction
in older mice [35]. A recent report suggested that Reb increased
the barrier function and controlled TNF-a-induced barrier
disruption via modulating cytokine expression in corneal epithelial
cells [7]. Reb may contribute to the anti-inflammatory effect on
exocrine glands or mucosal membrane through cytokines or
growth factors.
Most opthalmologists generally agree with the fact that topically
applied eyedrops penetrate into adjacent tissues mainly through
the cornea and partially through the conjunctiva. Many cases of
vernal keratoconjunctivitis with giant papillary conjunctivitis can
be treated using the topical administration of steroids or
immunosuppressants, and the giant papillae reduce in size. An
epidemiological study accounts for the fact that topically applied
eyedrops partially penetrate into the conjunctiva [36]. We believe
that it would be reasonable to conclude that rebamipide partially
penetrates into the conjunctival papillae and works as an anti-
inflammatory agent because the In-Lg is located close to the
conjunctiva papillae.
In conclusion, we showed here that Reb exerts both anti-
inflammatory and mucosal protective functions for effective
treatment of ocular lesions that occur in SS. Because the molecular
mechanisms underlying the therapeutic effects of topical Reb
administration remain unclear, further research is required to
establish appropriate treatments for SS.
Materials and Methods
Ethics
This study was conducted according to the Fundamental
Guidelines for Proper conduct of Animal Experiment and related
Activities in Academic Research Institutions under the jurisdiction
of the Ministry of Education, Culture, Sports, Science and
Technology of Japanese Government. The protocol was approved
by the Committee on the Animal Experiments of the University of
Tokushima (Permit Number: toku-09021). All experiment was
performed under ketamine and xylazin anesthesia, and all efforts
were made to minimize suffering.
Mice and experimental design
NFS/sld female mice with a mutant sld were reared in our
specific pathogen-free mouse colony and were provided with food
and water ad libitum at a constant ambient temperature (222
24uC) under a constant day-night rhythm. Thymectomy was
performed on these mice on day 3 after birth [10]. Reb eyedrops
(0%, 0.3%, and 1%) were formulated at Otsuka Pharmaceutical
Co. Ltd., and 2 ml of these drops was applied to each eye of mice
aged 4–8 weeks four times daily. After the administration during
4 weeks, mice were analyzed.
Tear secretion measurements
Tear volumes of Reb-treated mice were determined using a
previously described method [37,38]. In brief, to measure tear
secretion in pilocarpine-stimulated mice, mice were anesthetized
with ketamine (60 mg/kg body weight) and xylazin (6 mg/kg), and
then intraperitoneally injected with pilocarpine (2.5 mg/kg)
(Wako, Osaka, Japan). Tear volume was determined by measuring
the length of the phenol-red thread (Showa Yakuhin Kako Co.,
Ltd., Tokyo, Japan) left in contact with the eye every 5 min after
injection of pilocarpine until 10 min. Tear secretion was calculated
as tear volume/body weight.
Evaluation of ocular surfaces
We prepared a fluorescein liquid by dilating Fluorescite
intravenous injection 500 mg (Alcon Japan, Tokyo) by 2% with
saline. One to 2 mL of the liquid was administered to the cornea by
micropipette, and the residual liquids around the eye were washed
by saline and wiped by filter paper gently. After fluorescein
staining of the eye, the cornea was examined for corneal epithelial
disorders using a slit-lamp microscope with a blue filter; these
disorders were evaluated using a modified, previously described
method [39]. In brief, corneal epithelial disorders were scored on a
Figure 4. Anti-inflammatory proteins in the ocular lesions in
Reb-treated murine model of SS. The mRNA expression levels of
TGF-b (A), IL-10 (B), and mucin 5AC (C) in conjunctival tissues in Reb-
treated (0% and 1%) mice were analyzed using real-time RT-PCR. Results
expressed as mean 6 SD for five mice per group.
doi:10.1371/journal.pone.0098390.g004
Figure 5. Lactoferrin in tears from Reb-treated mice and direct effect of Reb on lacrimal glands. (A) The lactoferrin concentrations in the
tears from Reb-treated mice were determined using ELISA. Results are expressed as mean 6 SD for five mice per group. (B) Lacrimal gland cells from
Tx-NFS/sld mice were cultured with or without Reb (0.25 mM) for 6 h, and the lactoferrin mRNA levels in cultured Lg fragments were then analyzed
using real-time RT-PCR. Results are expressed as mean 6 SD of triplicate determinations per group from 3 independent experiments. *P,0.05, **P,
0.01.
doi:10.1371/journal.pone.0098390.g005
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scale of 0–3 as follows: 0, no punctate staining (normal); 1, sparse
punctate staining; 2, intermediate staining between 1 and 3; and 3,
dense punctate staining. The analysis was performed in a double-
blind manner.
Histological evaluations
After the mice were sacrificed, all the organs were removed,
fixed in 10% phosphate-buffered formaldehyde (pH 7.2), and
prepared for histological examination. Formalin-fixed tissue
sections were stained with hematoxylin and eosin. These were
independently evaluated by three pathologists in a blinded
manner. Inflammatory lesions of the lacrimal glands were
histopathologically evaluated as previously described [40].
Quantitative real-time reverse transcription-polymerase
chain reaction analysis
Total RNA was extracted from conjunctival tissues using
ISOGEN (Wako Pure Chemical Industries, Ltd., Osaka, Japan)
was and reverse transcribed. Transcripts of target genes and b-
actin were prepared using a 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA) with SYBR Premix Ex Taq
(Takara Bio, Shiga, Japan). The primer sequences used were as
follows: TGF-b: forward, 59-GACCGCAACAACGCCATCTAT-
39 and reverse, 59-GGCGTATCAGTGGGGGTCAG-39; IL-10:
forward, 59-ATCGATTTCTCCCCTGTGAA-39 and reverse, 59-
TGTCAAATTCATTCATGGCCT-39; mucin 5AC: forward, 59-
AAAGACACCAGTAGTCACTCAGCAA-39 and reverse, 59-CT-
GGGAAGTCAGTGTCAAACCA-39; lactoferrin: forward, 59-
ACAATGCTGGAGATGTGGCT-39 and reverse, 59-TTGTCA-
TTCGTGCTTCGGGA-39; and b-actin: forward, 59-GTGGGC-
CGCTCTAGGCACCA-39 and reverse, 59-CGGTTGGCCTT-
AGGGTTCAGGGGG-39. Relative mRNA abundance of each
transcript was normalized against b-actin.
Lactoferrin in tears
In mice injected with pilocarpine (2.5 mg/kg), tears from the
lateral canthus were collected using a 5-ml glass capillary tube
(Hirschmann Laborgera¨te GmbH & Co., Eberstadt, Germany) for
20 min. Collected tears were suspended in Pro-prep protein
extraction solution (iNtRON Biotechnology, Kyunggi-do, Korea)
and centrifuged, and supernatants were added to phosphate-
buffered saline (final volume: 100 ml). The concentrations of
lactoferrin in tears were determined using a Lactoferrin ELISA kit
(USCN Life Science Inc., Wuhan, China).
Organ culture of extraorbital lacrimal glands (Ex-Lg)
Female thymectomized NFS/sld mice were anesthetized, and
the lacrimal gland tissues were resected. The Ex-Lg were cut into
pieces less than 1 mm3. Tissue fragments were cultured at 37uC
with or without 0.25 mM Reb in a highly gas-permeable Imaging
Plate FC (Zell-Kontakt GmbH, No¨rten-Hardenberg, Germany)
containing Dulbecco’s modified Eagle medium (DMEM) with
10% fetal bovine serum, 2.5 mM dexamethasone, 10 mg/ml
insulin, 5.5 mg/ml transferrin, 6.7 ng/ml sodium selenite, 25 mg/ml
ascorbic acid, 10 ng/ml epidermal growth factor, 10 mg/ml reduced
glutathione, 5 mg/ml amphotericin B, 100 mg/ml streptomycin,
and 100 units/ml penicillin in an atmosphere containing 5%
CO2. After culture for 6 h, total RNA was prepared from these
cultured fragments for quantitative RT-PCR analysis to
determine the direct effects of Reb on exocrine gland tissues.
Immunohistochemistry
Paraffin-embedded sections were stained with rabbit anti-
lactoferrin antibodies (Abcam) using the biotin-avidin immuno-
peroxidase complex reagent (Dako). Nuclei were counterstained
with hematoxylin.
Statistical analysis
Statistical comparisons were performed using the Dunnett’s
(Figure 1), lower-tailed Shirley–Williams (Figures 2 and 3), and
unpaired Student t-tests (Figures 4 and 5).
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